Substance / Medication

Gatifloxacin

Overview

Active Ingredient
gatifloxacin
RxNorm CUI
228476

Indications

Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: * Efficacy for these organisms were studied in fewer than 10 infections. • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis * group Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae

Labeler: Sandoz IncUpdated: 2021-08-31T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Warnings and Precautions (5.1) [see]. Gatifloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

22 trials linked to this intervention

22
Total Trials
4
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
Ruan Qiaoling, Liu Qihui, Sun Feng et al. · Emerg Microbes Infect · 2016
PMID: 26905025Meta-AnalysisFull text (PMC)
Effect of gatifloxacin in the treatment of ophthalmological diseases and continuous nursing intervention.
Hezhen Tang, Shuying Wei, Xiaoli Zheng et al. · Pak J Pharm Sci · 2018
PMID: 30203767RCT
Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.
Olliaro Piero L, Merle Corinne, Mthiyane Thuli et al. · Antimicrob Agents Chemother · 2017
PMID: 28438924RCTFull text (PMC)
The effect of gatifloxacin 0.3% or moxifloxacin 0.5% on corneal healing, ocular tolerability and toxicity following pterygium surgery.
Mimouni Michael, Geffen Noa, Rosen Eli et al. · Cutan Ocul Toxicol · 2016
PMID: 25597371RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Gatifloxacin (substance)
SNOMED CT
116349004
UMLS CUI
C0753645
RxNorm CUI
228476
Labeler
Sandoz Inc

Clinical Data

This intervention maps to 20 entities in the Healos knowledge graph.

20
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
22
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.